Trial Profile

Phase I Clinical Trial Protocol for Tolerability and Pharmacokinetics of TQB3455 Tablets in Patients With Hematological Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TQB 3455 (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; Therapeutic Use
Sponsors Chia Tai Tianqing Pharmaceutical Group

Most Recent Events

10 Dec 2024 Results(Between June 3, 2022, and May 31, 2024 , n=21) evaluating the safety and efficacy of TQB3455 plus azacitidine in patients, presented at the 66th American Society of Hematology Annual Meeting and Exposition
19 Aug 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com